Cizin 10 mg (Tablet)
Unit Price: ৳ 2.00 (100's pack: ৳ 200.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Cetirizine hydrochloride |
| Company | Nipa pharmaceuticals ltd |
| Also available as |
Indications
- Relief of symptoms associated with seasonal & perennial allergic rhinitis
- Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria
- Treatment of allergen induced asthma
Pharmacology
- Potent H1 receptor antagonist
- No significant anticholinergic and antiserotonic effects
- Inhibition of histamine-mediated early phase of allergic reaction
- Reduction of migration of inflammatory cells and release of mediators associated with the late phase of allergic reaction
- Peak plasma concentrations of 257 mcg/L within one hour of administration
- Plasma half-life of approximately 11 hours
Dosage & Administration
- Adults and Children 6 years and older: 1 tablet or 2 teaspoonfuls daily
- Children 2-6 years: 1 teaspoonful once daily or 1/2 teaspoonful twice daily
- Children 6 months to 2 years: 1/2 teaspoonful once daily
- Cetirizine injectable dosage form for intravenous administration only
- Recommended dosage regimen for adults and adolescents 12 years of age and older: 10 mg by intravenous injection
- Recommended dosage regimen for children 6 to 11 years of age: 5 mg or 10 mg by intravenous injection
- Recommended dosage regimen for children 6 months to 5 years of age: 2.5 mg by intravenous injection
Interaction
- No clinically significant drug interactions found with Theophylline, Azithromycin, Pseudoephedrine, Ketoconazole, or Erythromycin
Contraindications
- History of hypersensitivity to Cetirizine or hydroxyzine
Side Effects
- Somnolence
Pregnancy & Lactation
- US FDA Pregnancy Category B
- Caution advised in use during pregnancy
- Excretion in human milk
- Caution advised when administered to a nursing woman
Precautions & Warnings
- Caution advised when driving a car or operating heavy machinery
Use in Special Populations
- Total body clearance of Cizin reduced in patients with mild to moderate hepatic and renal impairment
- Safety demonstrated in pediatric patients aged 6 months to 5 years
- Clearance reduced in elderly patients in proportion to decrease in creatinine clearance
Therapeutic Class
- Sedating Anti-histamine
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children